Lineage Cell Therapeutics (LCTX) Preferred Shares (2014 - 2015)
Lineage Cell Therapeutics (LCTX) posted quarterly Preferred Shares of $3.5 million for Q2 2015, little changed year-over-year from $3.5 million in Q2 2014, and little changed quarter-over-quarter from $3.5 million in Q1 2015.
Lineage Cell Therapeutics (LCTX) Preferred Shares (2014 - 2015) Analysis & Trends
Lineage Cell Therapeutics' Preferred Shares history runs 2 years deep, the most recent figure standing at $3.5 million for Q2 2015.
- In Q2 2015, Preferred Shares changed 0.0% year-over-year to $3.5 million; the TTM figure through Jun 2015 stood at $3.5 million (changed 0.0% YoY), while the FY2014 annual figure was $3.5 million, changed N/A from the prior year.
- Preferred Shares for Q2 2015 stood at $3.5 million, roughly flat from $3.5 million in the prior quarter.
- The five-year high for Preferred Shares was $3.5 million in Q1 2014, with the low at $3.5 million in Q1 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2015 | 3.50 Mn |
| Mar 31, 2015 | 3.50 Mn |
| Dec 31, 2014 | 3.50 Mn |
| Sep 30, 2014 | 3.50 Mn |
| Jun 30, 2014 | 3.50 Mn |
| Mar 31, 2014 | 3.50 Mn |